BeOne Medicines (ONC) Total Non-Current Liabilities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Total Non-Current Liabilities data on file, last reported at $2.0 billion in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 453.09% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 453.09% YoY) and the FY2025 annual result came in at $2.0 billion, up 434.67% from the prior year.
• Total Non-Current Liabilities fell to $2.0 billion in Q1 2026 per ONC's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $2.0 billion in Q4 2025 and bottomed at $318.1 million in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $525.1 million (2023), against an average of $705.7 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities tumbled 34.35%; it then soared 453.09% in 2026.
• Tracing ONC's Total Non-Current Liabilities over 5 years: stood at $527.4 million in 2022, then fell by 13.19% to $457.8 million in 2023, then declined by 18.36% to $373.8 million in 2024, then surged by 434.67% to $2.0 billion in 2025, then declined by 0.84% to $2.0 billion in 2026.
• Per Business Quant, the three latest ONC Total Non-Current Liabilities figures stand at $2.0 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.1 billion (Q3 2025).

Peer Comparison